Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) Accumulated Depreciation & Amortization (2019 - 2025)

ADC Therapeutics has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $1.4 million for Q4 2025, down 74.04% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (down 74.04% YoY), and the annual figure for FY2025 was $1.4 million, down 74.04%.
  • Accumulated Depreciation & Amortization reached $1.4 million in Q4 2025 per ADCT's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.4 million in Q2 2025 and bottomed at $129000.0 in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $4.7 million (2024), compared with a mean of $4.0 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 1142.73% in 2023 before it crashed 74.04% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $129000.0 in 2021, then soared by 166.67% to $344000.0 in 2022, then soared by 1142.73% to $4.3 million in 2023, then increased by 24.44% to $5.3 million in 2024, then crashed by 74.04% to $1.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ADCT at $1.4 million in Q4 2025, $6.3 million in Q3 2025, and $6.4 million in Q2 2025.